Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00879905 | A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 64 | — | — | May 1, 2009 | Jul 1, 2012 | Dec 8, 2020 | 3 | Canada, France +1 |
| Arm | Type | Description |
|---|---|---|
| once weekly dosing schedule | EXPERIMENTAL | - |
| twice weekly dosing schedule | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HSP990 | DRUG | - |
Inclusion Criteria: 1. Patients with histologically confirmed, advanced malignant solid tumors whose disease has progressed on standard therapy or for whom no standard therapy exists 2. All patients must have at least one measurable lesion as defined by RECIST. Irradiated lesions are only evaluable...